Tonix Pharmaceuticals Holding Corp. (TNXP)

Over the past six months, Tonix Pharmaceuticals' stock price has declined. Key events impacting the stock include the commercial launch of TONMYA, which showed initial success with healthcare provider prescriptions and patient treatment initiations. The company reported a significant net loss in the fourth quarter of 2025 and completed capital raises, contributing to share dilution. Tonix Pharmaceuticals' stock underwent a reverse split before market open on Wednesday, February 5th, 2025. Pipeline advancements, such as Phase 1 data for TNX-4800 and plans to initiate a Phase 2 trial for TNX-102 SL, have also been reported.

There is specific mention of demand seasonality for TNX-4800, a humanized monoclonal antibody being developed for the seasonal prevention of Lyme disease. The program envisions a single subcutaneous injection administered in the spring to provide protection through the fall, covering the entire tick season in the United States. For the company's other products and pipeline candidates, there is no explicit information to suggest significant demand seasonality.

Tonix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and diagnostics for CNS disorders, immunology, immuno-oncology, infectious diseases, and rare diseases. Its marketed products include TONMYA for fibromyalgia, Zembrace SymTouch, and Tosymra for migraine. The company has an extensive development pipeline targeting various conditions across CNS disorders, immunology, immuno-oncology, infectious diseases, and rare diseases.

Tonix Pharmaceuticals primarily develops and commercializes its therapies in the United States. The company is based in Berkeley Heights, New Jersey, and has a research and development center in Frederick, Maryland.

Tonix Pharmaceuticals' brand reputation has been shaped by the FDA approval and commercial launch of TONMYA, which was a positive event. However, the company's reputation has also been impacted by persistent net losses, increased cash burn, and substantial shareholder dilution from equity offerings and multiple reverse stock splits.

Tonix Pharmaceuticals has 72 institutional owners and shareholders holding a total of 3,743,021 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Point72 Asset Management, L.P., Geode Capital Management, Llc, State Street Corp, Balyasny Asset Management Llc, Northern Trust Corp, Nuveen, LLC, UBS Group AG, and Davidson Kempner Capital Management Lp. The largest individual shareholder is Seth Lederman, who owns 5.87 million shares, representing 43.78% of the company.